DPP-4 inhibitors block cleavage of incretin hormones glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide (13), modify glucose and postprandial lipid levels, and are an approved medication for type 2 diabetes. The gene discussed is GCG; the disease is type 2 diabetes mellitus.